Novel drug candidates for the treatment of castrate resistant prostate cancer

Prostate cancer cells learn to grow without the male hormones that drugs are designed to cut off, and a company called CellCentric has identified an enzyme that drives this lethal adaptation. This matters because castration-resistant prostate cancer (CRPC) develops in 10–20% of prostate cancer patients and is the form of the disease that kills. Current treatments eventually fail because the cancer finds a way around hormone deprivation. CellCentric already has prototype compounds that block the newly identified enzyme, but these are not yet potent or stable enough to test in animals. If the team can optimise these inhibitors into drug-like molecules, they will test them in laboratory models of CRPC. Success would produce a candidate compound ready for human clinical trials—a potential new treatment for a form of prostate cancer that currently has limited options once hormone therapy stops working. This is early-stage drug discovery, not a cure in hand, but it targets a specific molecular mechanism that could give patients a new line of defence.